414 F.Supp.3d 635
S.D.N.Y.2019Background
- Takeda developed ACTOS and ACTOplus and listed multiple patents (including composition and method-of-use claims) in the FDA "Orange Book." In January 2010 Takeda told the FDA the patents were properly described as drug-product and method-of-use patents in response to a Sandoz citizen petition.
- Multiple generics (Mylan, Actavis, Ranbaxy — the first filers) filed Paragraph IV ANDAs in 2003 challenging Takeda's patents; Teva later filed ANDAs. Litigation was consolidated and later settled in 2010.
- The March–December 2010 settlements granted the first generics non‑exclusive licenses to enter on August 17, 2012 (with coordination clauses allowing earlier entry if others entered sooner) and granted Teva an authorized‑generic distributorship during the first 180 days. Some agreements included distribution/authorized‑generic terms.
- Direct‑Purchaser Plaintiffs (DPPs) allege (1) monopolization by Takeda based on its January 2010 Orange Book statements that delayed generic entry, and (2) that the 2010 settlement agreements — and an alleged single conspiracy among Takeda and generics — unlawfully restrained trade and perpetuated monopoly (a novel, non‑reverse‑payment theory).
- District court disposition on motions to dismiss: denied Takeda's motion as to the monopolization claim based on its January 2010 FDA statements (Count I proceeds); granted dismissal of Counts II–VIII (claims premised on the settlement agreements and overarching conspiracy). Leave to amend denied; stay lifted.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Monopolization based on Takeda's Jan 2010 Orange Book statements | Takeda's representations to FDA were false/misleading, delayed generic entry and caused antitrust injury | Takeda's statements were lawful or insufficiently pleaded to show antitrust injury | Court: DPPs plausibly alleged Takeda's statements were anti‑competitive and caused delay; monopolization claim (Count I) survives |
| Legality of 2010 settlement agreements under a non‑reverse‑payment theory | Settlements exploited the "undeserved" 180‑day exclusivity (obtained via Takeda's statements) and prolonged supra‑competitive pricing; agreements are unlawful restraints | Settlements are permitted patent‑litigation compromises under Actavis; novel theory lacks precedent and would deter settlement | Court: Novel theory rejected as inconsistent with Actavis; claims based on settlements (Counts II–VIII) dismissed |
| Whether first‑filers knew Orange Book descriptions were false when settling | First filers were "regulatory savvy," filed split certifications, and therefore must have known descriptions were drug‑product claims and false | Allegations do not plausibly show first filers knew the patent descriptions were false; knowledge of listing ≠ knowledge of falsity | Court: Plaintiffs failed to plead plausible facts that first‑filers knew descriptions were false; allegations insufficient |
| Teva's settlement — did it cause antitrust injury? | Teva joined the conspiracy and its settlement further delayed Teva's market entry | Teva was not a first‑filer and could not have entered earlier because statutory 180‑day exclusivity would have blocked final approval; alternative timelines are speculative | Court: DPPs' causal scenarios are too speculative; antitrust injury not plausibly alleged as to Teva; claim dismissed |
| Overarching conspiracy and leave to amend | DPPs allege a single multidefendant conspiracy to perpetuate monopoly via settlements | Defendants: no unlawful underlying agreement; allegations are conclusory or implausible | Court: Conspiracy claims dismissed; leave to amend denied as futile |
Key Cases Cited
- FTC v. Actavis, Inc., 570 U.S. 136 (2013) (Supreme Court: reverse‑payment patent settlements are subject to rule‑of‑reason antitrust review)
- Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S, 566 U.S. 399 (2012) (Supreme Court: generics may counterclaim to require removal/correction of Orange Book patent listings)
- In re Actos End‑Payor Antitrust Litig., 848 F.3d 89 (2d Cir. 2017) (Second Circuit decision addressing Orange Book issues and related procedural history)
- FTC v. AbbVie Inc., 107 F. Supp. 3d 428 (E.D. Pa. 2015) (district court decision refusing to subject Paragraph IV settlements to antitrust scrutiny based on a theory that generics knowingly settled sham litigation)
- Professional Real Estate Investors, Inc. v. Columbia Pictures Indus., Inc., 508 U.S. 49 (1993) (Supreme Court: standards for sham‑litigation antitrust claims)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (Supreme Court: pleading standard for plausibility on a motion to dismiss)
- AstraZeneca LP v. Apotex, Inc., 663 F.3d 1042 (Fed. Cir. 2010) (Fed. Cir.: possible injunctions when generic labeling may induce infringement)